Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Triad Therapeutics Inc.

This article was originally published in Start Up

Executive Summary

Triad Therapeutics Inc. hopes to accelerate the drug discovery process through the use of its IOPE technology, which it claims significantly accelerates the discovery of nanomolar-affinity hits over those obtained with other currently available technologies. IOPE exploits NMR spectroscopy to map key structural elements among the members of individual classes of enzymes and then uses the data to design libraries of compounds biased to bind to targets of the class, in effect starting the medicinal chemistry process with a compound that is much closer to a development lead.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC090266

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel